Antibodies against human and canine il-13ra2
AssigneeWake Forest University Health Sciences
InventorsWaldemar Debinski, Denise Mazess Herpai
Life of this patent
Estimating the term…
Abstract
Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
Claims28
-17. (canceled)
A method of treating a tumor in a subject in need thereof comprising administering to said subject in a treatment effective amount an antibody that specifically binds an epitope within amino acids spanning the extracellular portion of human IL-13RA2.
A method of inhibiting cancer metastasis in a subject in need thereof comprising administering to said subject in a treatment effective amount an antibody that specifically binds an epitope within amino acids spanning the extracellular portion of human IL-13RA2.
A method of detecting a cancer in a subject in need thereof comprising administering to said subject an antibody that specifically binds an epitope within amino acids spanning the extracellular portion of human IL-13RA2, wherein said antibody is coupled to a detectable group, in an amount effective to detect said antibody.
Dependencies are inferred from the claim text.